Biotheus Inc.
Biotheus Inc.
Explore linked clinical trials.10 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-07-29 | NCT06419621 | |
| PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 2 | 2026-07-23 | NCT07133750 | |
| A Study of PM8002 in Combination With Chemotherapy in Patients With NEN | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2026-07-09 | NCT05879055 | |
| PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer | SCLC | Active, not recruiting | Phase 3 | 2026-05-22 | NCT06616532 | |
| A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC | non-small cell lung carcinoma | Active, not recruiting | Phase 2 | 2025-04-03 | NCT05756972 | |
| A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC | SCLC | Active, not recruiting | Phase 2 | 2025-03-12 | NCT05844150 | |
| A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC | TNBC | Active, not recruiting | Phase 1 / Phase 2 | 2025-03-11 | NCT05918133 | |
| A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC | SCLC | Active, not recruiting | Phase 2 | 2024-12-18 | NCT05879068 | |
| A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Site, hepatocellular carcinoma, liver cancer, liver disorder, neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2024-12-16 | NCT06584071 | |
| PM8002 in the Treatment of Patients With Advanced Solid Tumors | cancer, neoplasm | Recruiting | Phase 1 / Phase 2 | 2024-12-05 | NCT05918445 |